Toggle light / dark theme

💠 Japanese researchers have created a “nose” mosquito that can detect odors from tiny droplets of liquid droplets. The research could lead to the creation of Smell-O-Vision for machines and a means of diagnosing early cancer, they say. Japanese researchers have created a “nose” that can detect different odors at the same time. The team used two bubbles, each filled with oil, broken horizontally, to create a squinted figure-eight. They hope to use it to develop an artificial nose in the future.

Researchers have developed a “bionic nose” that can detect odor molecules. The team hopes to use the device as an inexpensive way to diagnose the early stages of illness. Eventually, the team wants to use their bionic nose for cancer and other health issues. They hope to make the device available to the public soon.

Thanks and Enjoy đŸ”„ đŸ”„
- -
đŸŽ„ #BioEngineering #Mosquitoes #Cells.

Sources:
⚉ https://www.nature.com/articles/nature.2014.14904#:~:text=The%20human%20nose%20has%20roughly, report%20today%20in%20Science1.
⚉ https://www.eurekalert.org/pub_releases/2021-01/uot-hdy011121.php.
⚉ https://advances.sciencemag.org/content/7/3/eabd2013

An aging/longevity/junk dna link.

~~~


The human body is essentially made up of trillions of living cells. It ages as its cells age, which happens when those cells eventually stop replicating and dividing. Scientists have long known that genes influence how cells age and how long humans live, but how that works exactly remains unclear. Findings from a new study led by researchers at Washington State University have solved a small piece of that puzzle, bringing scientists one step closer to solving the mystery of aging.

A research team headed by Jiyue Zhu, a professor in the College of Pharmacy and Pharmaceutical Sciences, recently identified a DNA region known as VNTR2-1 that appears to drive the activity of the telomerase gene, which has been shown to prevent aging in certain types of . The study was published in the journal Proceedings of the National Academy of Sciences (PNAS).

The telomerase gene controls the activity of the telomerase enzyme, which helps produce telomeres, the caps at the end of each strand of DNA that protect the chromosomes within our cells. In normal cells, the length of telomeres gets a little bit shorter every time cells duplicate their DNA before they divide. When telomeres get too short, cells can no longer reproduce, causing them to age and die. However, in certain cell types—including reproductive cells and —the activity of the telomerase gene ensures that telomeres are reset to the same length when DNA is copied. This is essentially what restarts the aging clock in new offspring but is also the reason why cells can continue to multiply and form tumors.

For decades, scientists have been trying to build a long-lasting replacement for the human heart. Now, an Australian inventor believes he’s cracked one of the hardest problems in medicine.

#Prognosis #Science #BloombergQuicktake.
——-
Like this video? Subscribe: http://www.youtube.com/Bloomberg?sub_confirmation=1
Become a Quicktake Member for exclusive perks: http://www.youtube.com/bloomberg/join.

QuickTake Originals is Bloomberg’s official premium video channel. We bring you insights and analysis from business, science, and technology experts who are shaping our future. We’re home to Hello World, Giant Leap, Storylines, and the series powering CityLab, Bloomberg Businessweek, Bloomberg Green, and much more.

Subscribe for business news, but not as you’ve known it: exclusive interviews, fascinating profiles, data-driven analysis, and the latest in tech innovation from around the world.

Visit our partner channel QuickTake News for breaking global news and insight in an instant.

In March 2017, Read and his Penn State colleague David Kennedy published a paper in the Proceedings of the Royal Society B in which they outlined several strategies that vaccine developers could use to ensure that future vaccines don’t get punked by evolutionary forces. One overarching recommendation is that vaccines should induce immune responses against multiple targets. A number of successful, seemingly evolution-proof vaccines already work this way: After people get inoculated with a tetanus shot, for example, their blood contains 100 types of unique antibodies, all of which fight the bacteria in different ways. In such a situation, it becomes much harder for a pathogen to accumulate all the changes needed to survive. It also helps if vaccines target all the known subpopulations of a particular pathogen, not just the most common or dangerous ones. Richard Malley and other researchers at Boston Children’s Hospital are, for instance, trying to develop a universal pneumococcal vaccine that is not serotype-specific.

Vaccines should also bar pathogens from replicating and transmitting inside inoculated hosts. One of the reasons that vaccine resistance is less of a problem than antibiotic resistance, Read and Kennedy posit, is that antibiotics tend to be given after an infection has already taken hold — when the pathogen population inside the host is already large and genetically diverse and might include mutants that can resist the drug’s effects. Most vaccines, on the other hand, are administered before infection and limit replication, which minimizes evolutionary opportunities.

But the most crucial need right now is for vaccine scientists to recognize the relevance of evolutionary biology to their field. Last month, when more than 1000 vaccine scientists gathered in Washington, D.C., at the World Vaccine Congress, the issue of vaccine-induced evolution was not the focus of any scientific sessions. Part of the problem, Read says, is that researchers are afraid: They’re nervous to talk about and call attention to potential evolutionary effects because they fear that doing so might fuel more fear and distrust of vaccines by the public — even though the goal is, of course, to ensure long-term vaccine success. Still, he and Kennedy feel researchers are starting to recognize the need to include evolution in the conversation. “I think the scientific community is becoming increasingly aware that vaccine resistance is a real risk,” Kennedy said.

“What is exciting about this is that although our study was only in mice, the same mechanism should operate in humans – the molecules and structures in the human brain are the same as those in rodents,” says Fawcett. “This suggests that it may be possible to prevent humans from developing memory loss in old age.”


An intriguing new study from researchers in the United Kingdom is proposing an innovative method to treat age-related memory loss. The preclinical research shows memory decline in aging mice can be reversed by manipulating the composition of structures in the brain known as perineuronal nets.

Perineuronal nets (PNNs) are structures in the brain that envelop certain subsets of neurons, helping stabilize synaptic activity. They essentially put the brakes on the neuroplasticity seen in the first few years of life.

Although PNNs are vital to the effective functioning of a mature adult brain, by their very nature they also limit future neural plasticity and adaptability. A new wave of research is beginning to investigate ways to modulate PNNs in adult brains in the hope of treating a variety of diseases from diabetes to post-traumatic stress disorder (PTSD).

Gain-of-function experiments aim to increase the transmissibility and virulence of existing viruses, making them deadlier for humans. The stated purpose is to better understand pathogens and to develop vaccines for possible future pandemics. Critics say this type of research is extremely dangerous and should be banned or regulated. They claim it has not prevented any pandemics to date, and that the COVID-19 outbreak might be the result of an accidental release from a lab that was conducting gain-of-function research.

Subscribe: https://www.youtube.com/user/deutschewelleenglish?sub_confirmation=1

For more news go to: http://www.dw.com/en/
Follow DW on social media:
â–șFacebook: https://www.facebook.com/deutschewellenews/
â–șTwitter: https://twitter.com/dwnews.
â–șInstagram: https://www.instagram.com/dwnews.
FĂŒr Videos in deutscher Sprache besuchen Sie: https://www.youtube.com/dwdeutsch.

#biosafety #GainOfFunction #pandemic

DeepMind and EMBL release the most complete database of predicted 3D structures of human proteins.

Partners use AlphaFold, the AI system recognized last year as a solution to the protein structure prediction problem, to release more than 350000 protein structure predictions including the entire human proteome to the scientific community.

DeepMind today announced its partnership with the European Molecular Biology Laboratory (EMBL), Europe’s flagship laboratory for the life sciences, to make the most complete and accurate database yet of predicted protein structure models for the human proteome. This will cover all ~20000 proteins expressed by the human genome, and the data will be freely and openly available to the scientific community. The database and artificial intelligence system provide structural biologists with powerful new tools for examining a protein’s three-dimensional structure, and offer a treasure trove of data that could unlock future advances and herald a new era for AI-enabled biology.

Brain–computer interfaces (BCIs) provide bidirectional communication between the brain and output devices that translate user intent into function. Among the different brain imaging techniques used to operate BCIs, electroencephalography (EEG) constitutes the preferred method of choice, owing to its relative low cost, ease of use, high temporal resolution, and noninvasiveness. In recent years, significant progress in wearable technologies and computational intelligence has greatly enhanced the performance and capabilities of EEG-based BCIs (eBCIs) and propelled their migration out of the laboratory and into real-world environments. This rapid translation constitutes a paradigm shift in human–machine interaction that will deeply transform different industries in the near future, including healthcare and wellbeing, entertainment, security, education, and marketing. In this contribution, the state-of-the-art in wearable biosensing is reviewed, focusing on the development of novel electrode interfaces for long term and noninvasive EEG monitoring. Commercially available EEG platforms are surveyed, and a comparative analysis is presented based on the benefits and limitations they provide for eBCI development. Emerging applications in neuroscientific research and future trends related to the widespread implementation of eBCIs for medical and nonmedical uses are discussed. Finally, a commentary on the ethical, social, and legal concerns associated with this increasingly ubiquitous technology is provided, as well as general recommendations to address key issues related to mainstream consumer adoption.

When will Neuralink be available to healthy individuals? It’s difficult to find a coherent train of thought pertaining to this question specifically.

Recently, I’ve started thinking more in terms of regulatory approval rather than rough timeline estimates. This sent me down a fascinating path learning more about how medical devices in general make it through “the system.”

This video essay hopefully ties together that research in an accessible way that addresses the topic more directly.

Cheers.

Andrew.